Jacob Westman

This inventor holds 14 USPTO granted patents and 7 published patent applications and 10 EPO patents. Top assignees: Betagenon Ab, Curovir Ab, Dicot Pharma Ab. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jacob Westman. Retrieved from https://idiyas.com/inventor/jacob-westman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 7)

% Patents Active = 100.0

EPO Patents = 10 (Patent Applications = 13)

Average Co-Inventor Count = 1.7

ph-index = 2

Forward Citations = 12(Granted Patents)

Location History:

Blomsberg, SE (2015)
Jarlasa, SE (2013 - 2018)
Järlåsa, SE (2019 - 2021)
Järläsa, SE (2023)

Company Filing History:

Years Active: 2013-2026

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12643918 - Thiadiazolone derivatives and their use as AMPK agonists for the treatment of diabetes and related disorders (2026-06-02),

2. 12319696 - 2,6-dimethyl-n-((pyridin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine and 2,5-dimethyl-n-[(pyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine derivatives for treating viral infections (2025-06-03),

3. 12173011 - Compounds and methods of their manufacturing (2024-12-24),

4. 12162850 - Formulations (2024-12-10),

5. 12157744 - Compounds and methods of their manufacturing (2024-12-03),

6. 12152039 - Compounds and methods of their manufacturing (2024-11-26),

7. 11691954 - Formulations (2023-07-04),

8. 11001587 - Substituted indazoles as phosphatidylinositol kinase inhibitors (2021-05-11),

9. 10407429 - Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy (2019-09-10),

10. 9963455 - Pyrazolo[1,5-a]pyrimidines as antiviral compounds (2018-05-08),

11. 9675596 - 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer (2017-06-13),

12. 9162994 - 1,2,4-thiazoloidin-3-one derivatives and their use in the treatment of cancer (2015-10-20),

13. 8957092 - Quinoline derivatives and their use as tyrosine kinase inhibitors (2015-02-17),

14. 8557843 - Quinoline derivatives and their use as tyrosine kinase inhibitors (2013-10-15),

Title: Jacob Westman: Innovator in Viral Infection Treatment

Introduction

Jacob Westman is a prominent inventor based in Jarlasa, Sweden. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds aimed at treating viral infections. With a total of 13 patents to his name, Westman continues to push the boundaries of innovation in pharmaceutical research.

Latest Patents

Westman's latest patents include groundbreaking compounds such as 2,6-dimethyl-n-((pyridin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine and 2,5-dimethyl-n-[(pyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine derivatives. These compounds are designed for treating viral infections and represent a significant advancement in therapeutic options. The patents detail a compound of formula (I) or a pharmaceutically acceptable salt thereof, where one of X and Y is O and the other is N. The compounds also include various substituents that enhance their efficacy.

Career Highlights

Throughout his career, Jacob Westman has worked with notable companies such as Curovir AB and Betagenon AB. His work has focused on the synthesis and development of therapeutically active limonoids, as well as new limonoid-type compounds. His innovative approaches have led to the creation of methods for producing these compounds, which are crucial in the fight against viral infections.

Collaborations

Westman has collaborated with esteemed colleagues, including Catarina Malmberg and Allan Hallett. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic agents.

Conclusion

Jacob Westman is a key figure in the field of medicinal chemistry, with a strong focus on developing innovative treatments for viral infections. His extensive patent portfolio and collaborative efforts highlight his commitment to advancing pharmaceutical research.

Profile summary based on public USPTO records.